Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pleomorphic Lobular Breast Carcinoma

被引:2
|
作者
Goker, Menekse [1 ,2 ]
Deblaere, Stephanie [1 ]
Denys, Hannelore [2 ,3 ]
Vergauwen, Glenn [1 ,2 ]
Naert, Eline [2 ,3 ]
Veldeman, Liv [2 ,4 ]
Monten, Chris [2 ,4 ]
Van den Broecke, Rudy [1 ]
Van Dorpe, Jo [2 ,5 ]
Braems, Geert [1 ,2 ]
Van de Vijver, Koen [2 ,5 ]
机构
[1] Ghent Univ Hosp, Dept Gynaecol, B-9000 Ghent, Belgium
[2] Univ Ghent, Canc Res Inst Ghent GRIG, B-9000 Ghent, Belgium
[3] Ghent Univ Hosp, Dept Med Oncol, B-9000 Ghent, Belgium
[4] Ghent Univ Hosp, Dept Radiotherapy, B-9000 Ghent, Belgium
[5] Univ Ghent, Ghent Univ Hosp, Dept Pathol, B-9000 Ghent, Belgium
关键词
invasive lobular cancer; pleomorphic invasive lobular cancer; tumor-infiltrating lymphocytes; programmed cell death 1; programmed cell death ligand 1; SP142; assay; survival; EVENT-FREE SURVIVAL; LIGAND; EXPRESSION; PREDICTIVE-VALUE; CANCER; CHEMOTHERAPY; TRASTUZUMAB; PROGNOSIS; HISTOLOGY; BENEFIT; PDL1;
D O I
10.3390/cancers15112894
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognostic and predictive role of stromal tumor-infiltrating lymphocytes (sTILs) is undetermined in pleomorphic invasive lobular cancer (pILC). The same applies for the expression of PD-1/PD-L1 in this rare breast cancer subtype. Here, we aimed to investigate the expression of sTILs and analyze the PD-L1 expression levels in pILC. Methods: Archival tissues from sixty-six patients with pILC were collected. The sTIL density was scored as a percentage of tumor area using the following cut-offs: 0%; <5%; 5-9%; and 10-50%. The PD-L1 expression was analyzed using IHC on formalin-fixed, paraffin-embedded tissue sections using SP142 and 22C3 antibodies. Results: A total of 82% of the sixty-six patients were hormone receptor positive and 8% of cases were triple negative (TN), while 10% showed human epidermal growth factor receptor 2 (HER2) amplification. sTILs (=1%) were present in 64% of the study population. Using the SP142 antibody, 36% of tumors demonstrated a positive PD-L1 score of =1%, and using the 22C3 antibody, 28% had a positive PD-L1 score of =1. There was no correlation between sTILs or PD-L1 expression and tumor size, tumor grade, nodal status, expression of estrogen receptor (ER), or amplification of HER2. Our data did not show any difference in survival between the three molecular subtypes of pILC with respect to sTILs and PD-L1 expression. Conclusion: This study shows that pILCs show some degree of sTILs and PD-L1 expression; however, this was not associated with a survival improvement. Additional large trials are needed to understand immune infiltration in lobular cancer, especially in the pleomorphic subtype.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression
    Hanamura, Toru
    Kitano, Shigehisa
    Kagamu, Hiroshi
    Yamashita, Makiko
    Terao, Mayako
    Tsuda, Banri
    Okamura, Takuho
    Kumaki, Nobue
    Hozumi, Katsuto
    Harada, Naoki
    Iwamoto, Takayuki
    Honda, Chikako
    Kurozumi, Sasagu
    Niikura, Naoki
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [12] PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
    Wimberly, Hallie
    Brown, Jason R.
    Schalper, Kurt
    Haack, Herbert
    Silver, Matthew R.
    Nixon, Christian
    Bossuyt, Veerle
    Pusztai, Lajos
    Lannin, Donald R.
    Rimm, David L.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (04) : 326 - 332
  • [13] Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression
    Brcic, Iva
    Kluba, Andrea Maria
    Godschachner, Theresa Marie
    Suppan, Christoph
    Regitnig, Peter
    Dandachi, Nadia
    Lax, Sigurd Friedwald
    Balic, Marija
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [14] PD-L1 positive tumor-infiltrating lymphocytes and mutational load in breast cancer
    Sobral-Leite, Marcelo
    Van de Vijver, Koen
    Michaut, Magali
    Horlings, Hugo M.
    Severson, Tesa M.
    Schouten, Philip C.
    van der Linden, Rianne
    Kersten, Kelly
    Mulligan, Anna Marie
    Weerasooriya, Nayana
    Sanders, Joyce
    Cimino-Mathews, Ashley
    Peters, Dennis
    Hooijer, Gerrit K.
    Hooijberg, Erik
    Broeks, Annegien
    Bernards, Rene
    Linn, Sabine
    Andrulis, Irene L.
    van de Vijver, Marc J.
    Wessels, Lodewyk F.
    Kok, Marleen
    de Visser, Karin E.
    Schmidt, Marjanka K.
    CANCER RESEARCH, 2017, 77
  • [15] Relationship between PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Canine Mammary Tumor
    Lopes-Neto, Belarmino Eugenio
    Sousa Nunes-Pinheiro, Diana Celia
    Vale Carvalheira, Julio Gil
    Schmitt, Fernando
    Gartner, Maria de Fatima
    ACTA SCIENTIAE VETERINARIAE, 2021, 49
  • [16] Prognostic value of tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in cholangiocarcinoma
    Suleiman, Yaman
    Coppola, Domenico
    Zibadi, Sherma
    Dalia, Samir
    Juan, TzuHua
    Lee, Jae K.
    Malafa, Mokenge Peter
    Soliman, Hatem Hussein
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [17] Tumor Infiltrating Lymphocytes and PD-L1 Expression in Metastatic Breast Cancer
    Jacob, Jack
    Hazan, Rachel
    Albanese, Joseph M.
    Fineberg, Susan
    MODERN PATHOLOGY, 2018, 31 : 76 - 77
  • [18] Tumor Infiltrating Lymphocytes and PD-L1 Expression in Metastatic Breast Cancer
    Jacob, Jack
    Hazan, Rachel
    Albanese, Joseph M.
    Fineberg, Susan
    LABORATORY INVESTIGATION, 2018, 98 : 76 - 77
  • [19] PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients
    Toda, Yu
    Kohashi, Kenichi
    Yamada, Yuichi
    Ishihara, Shin
    Ito, Yoshihiro
    Yamamoto, Hidetaka
    Oda, Yoshinao
    CANCER SCIENCE, 2021, 112 : 514 - 514
  • [20] PD-L1 expression and tumor-infiltrating lymphocytes Revisiting the antitumor immune response potential in breast cancer
    Schalper, Kurt A.
    ONCOIMMUNOLOGY, 2014, 3 (06):